Abstract 2262P
Background
Current clinical paradigms are reliant on radiographic monitoring of disease to assess treatment response. However, this approach has some limitations including interval nature of imaging modalities and patients can clinically deteriorate prior to formally documenting therapy resistance. Hence, novel techniques such as longitudinal monitoring circulating tumor DNA (ctDNA) to assess therapy related response in real time are important to investigate.
Methods
To assess changes in disease burden with therapy, we profiled circulating tumor DNA (ctDNA) from longitudinal patient blood plasma using PredicineBEACON personalized minimal residual disease (MRD) assay and PredicineALERT, a tumor-agnostic MRD assay that measures cancer-related methylation patterns without personalization. Nineteen longitudinal plasma samples from 2 HER2+ gastroesophageal cancer (GEC) patients were tested using baseline-informed and tumor-agnostic MRD assays.
Results
Patient 1 demonstrated a similar trend of molecular dynamics and turning points of tumor response to therapy across 9 time points between the two MRD assays. Although the overall trends between the two assays were concordant for the second patient, some time points showed differential dynamics of changes in circulating levels of specific mutations compared to overall methylation profiling. An uptick levels of ctDNA after initial response preceeded radiographic progression using either approaches. Overall, in this ongoing study of the initial 2 cancer patients using 19 longitudinal blood samples, both PredicineALERT and PredicineBEACON assays demonstrated the trend of molecular dynamics and identified the similar turning points of tumor response during therapy.
Conclusions
Both tumor informed mutation based and tumor agnostic mehtylation based ctDNA approaches demonstrate clinical potential to monitor disease evolution and identify resistance prior to radiographic progression. Further study of such approaches to identify pre-radiographic molecular progression is warranted.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Du, G. Bonora, S. Jia: Financial Interests, Personal, Full or part-time Employment: Predicine. H. Singh: Other, Personal and Institutional, Research Funding: AstraZeneca; Financial Interests, Personal, Advisory Board: Merck, DewPoint therapeutics. P.C. Enzinger: Financial Interests, Advisory Role: ALX oncology, Arcus Bioscience, Astellas, AstraZeneca, Blueprint medicine, BMS, Chimeric Therapeutics, Celgene, Coherus, Daiichi Sankyo, Five Prime, IDEAYA, Istari, Legend, Lilly, Loxo, Merck, Novartis, Ono, Servier, Taiho, Takeda, Turning Point Therapeutics, Xencor, Zymeworks.
Resources from the same session
2274P - Deep learning-based prediction of pathologic complete response to neoadjuvant therapy in breast cancer using H&E images and RNA-Seq in the IMMUcan study
Presenter: Christian Esposito
Session: Poster session 08
2275P - Circulating leptin and adiponectin levels in premenopausal women with and without breast cancer (BC) and a body mass index (BMI) ≥25 kg/m2
Presenter: Isabel Calvo
Session: Poster session 08
2276P - Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer
Presenter: Young Ju Jeong
Session: Poster session 08
2277P - A colorimetric biosensor to track Trop-2 status of tumor cells for diagnosis of breast cancer
Presenter: Tianyu Zeng
Session: Poster session 08
2278P - Endothelial cell heterogeneity defined by single-cell spatial transcriptomic analysis of breast cancers
Presenter: Krisztian Homicsko
Session: Poster session 08
2279P - Glucocorticoid receptor antagonism and beta adrenergic receptor inhibition: Implications in triple-negative breast cancer brain metastasis
Presenter: Andra Antohi
Session: Poster session 08
2280P - MiR-193a-3p: A pan-repressor of H2S synthesizing enzymes regulates tumorigenesis and immunosurveillance in breast cancer
Presenter: Alyaa Dawoud
Session: Poster session 08
2281P - Multi-omics evaluation of TFE3-fusions and potential association with immuno-metabolic vulnerabilities in alveolar soft part sarcoma (ASPS) and translocation-positive renal cell carcinoma (tRCC)
Presenter: Shuanzeng Wei
Session: Poster session 08
2282P - Tissue glycan profiling in predicting immunotherapy response in renal cell carcinoma and hepatocelllular carcinoma
Presenter: Qin Jian Low
Session: Poster session 08
2283P - Assessing the replicative potential of the oncolytic virus VSV-GP in patient-derived tumor biopsies ex vivo
Presenter: Benjamin Schoeps
Session: Poster session 08